Novartis puts a €2.7bn BET on MorphoSys
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
Bayer and Lilly make radioligand progress
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.
Car-T comes full circle
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
